An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
Primary Purpose
Kidney Failure, Acute, Kidney Failure, Chronic, Cardiac Surgical Procedures
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
N-acetylcysteine
fenoldopam
Sponsored by
About this trial
This is an interventional prevention trial for Kidney Failure, Acute focused on measuring Kidney failure, Cardiac Surgery, Fenoldopam, N-acetylcysteine
Eligibility Criteria
Inclusion Criteria: Chronic creatinine clearance </= 40cc/h Pre-operative cardiac surgery Exclusion Criteria: Pre-operative ongoing dialysis Nausea and vomiting Uncontrolled glaucoma Allergy to metabisulfite Enrollment in another clinical study within 30 days Pregnancy Acute renal failure
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
NAC
fenoldopam
NAC and fenoldopam
Control
Arm Description
N-acetylcysteine started day prior to surgery, continued through night of surgery
fenoldopam started at surgery continued for 24 hours
Both N-acetylcysteine and fenoldopam as above
Placebo
Outcomes
Primary Outcome Measures
Length of post-operative hospital stay
Length of post-operative critical care stay
Creatinine clearance post-operative days 3, 14, and nadir
Secondary Outcome Measures
Days to post-operative creatinine clearance nadir
Intraoperative and post-operative pressor use (pressor-hours)
Hospital costs
Mortality
Full Information
NCT ID
NCT00122018
First Posted
July 14, 2005
Last Updated
November 6, 2014
Sponsor
Linda F. Barr, M.D.
Collaborators
Abbott
1. Study Identification
Unique Protocol Identification Number
NCT00122018
Brief Title
An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
Official Title
N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
May 2002 (undefined)
Primary Completion Date
March 2006 (Actual)
Study Completion Date
March 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Linda F. Barr, M.D.
Collaborators
Abbott
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients with abnormal kidney function are at increased risk for complications following heart surgery, including worsening kidney function possibly requiring dialysis, a prolonged stay in the critical care unit and hospital, and the increased risk of death. Prior attempts at kidney protection for heart surgery patients have had mixed results. Two medicines, fenoldopam and N-acetylcysteine, have been shown to protect kidney function in other circumstances that cause kidney stress. The purpose of this study is to determine whether these medications will help to maintain the function of diseased kidneys during heart surgery.
Detailed Description
This is a randomized, double-blinded, placebo-controlled trial to evaluate fenoldopam and N-acetylcysteine (NAC) individually, and together, as renal protective agents for patients with renal insufficiency undergoing heart surgery. Subjects have chronic renal insufficiency with creatinine clearance (CrCl) </= 40cc/min but not on pre-operative dialysis, and receive: NAC 600 mg by mouth (po) twice a day (bid) or placebo starting 24 hours pre-operative and continuing through the day of surgery; and/or fenoldopam 0.1 mcg/kg/min intravenous (IV) or saline placebo at anesthetic induction and continuing for 48 hours. Outcome data include: nadir, post-operative day 3 and post-operative day 14 CrCl, time to CrCl nadir, length of Intensive Care Unit (ICU) stay, length of post-operative hospital stay, hospital costs, mortality, and the need for hemodialysis. Intraoperative and post-operative pressor use is being monitored. The enrollment will include 80 patients (20 in each group).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Failure, Acute, Kidney Failure, Chronic, Cardiac Surgical Procedures
Keywords
Kidney failure, Cardiac Surgery, Fenoldopam, N-acetylcysteine
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
Double
Allocation
Randomized
Enrollment
80 (false)
8. Arms, Groups, and Interventions
Arm Title
NAC
Arm Type
Experimental
Arm Description
N-acetylcysteine started day prior to surgery, continued through night of surgery
Arm Title
fenoldopam
Arm Type
Experimental
Arm Description
fenoldopam started at surgery continued for 24 hours
Arm Title
NAC and fenoldopam
Arm Type
Experimental
Arm Description
Both N-acetylcysteine and fenoldopam as above
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
N-acetylcysteine
Other Intervention Name(s)
Mucomyst
Intervention Type
Drug
Intervention Name(s)
fenoldopam
Other Intervention Name(s)
Corlopam
Primary Outcome Measure Information:
Title
Length of post-operative hospital stay
Time Frame
30-day
Title
Length of post-operative critical care stay
Time Frame
30-day
Title
Creatinine clearance post-operative days 3, 14, and nadir
Time Frame
14 day
Secondary Outcome Measure Information:
Title
Days to post-operative creatinine clearance nadir
Time Frame
14 day
Title
Intraoperative and post-operative pressor use (pressor-hours)
Time Frame
48 hour
Title
Hospital costs
Time Frame
30-day
Title
Mortality
Time Frame
30-day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Chronic creatinine clearance </= 40cc/h
Pre-operative cardiac surgery
Exclusion Criteria:
Pre-operative ongoing dialysis
Nausea and vomiting
Uncontrolled glaucoma
Allergy to metabisulfite
Enrollment in another clinical study within 30 days
Pregnancy
Acute renal failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Linda F Barr, MD
Organizational Affiliation
Pulmonary and Critical Care Assoc. of Baltimore
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
18434903
Citation
Barr LF, Kolodner K. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Crit Care Med. 2008 May;36(5):1427-35. doi: 10.1097/CCM.0b013e31816f48ba.
Results Reference
result
Learn more about this trial
An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
We'll reach out to this number within 24 hrs